Loading…

Phase II clinical trial of a vas deferens injectable contraceptive for the male

Following up on an earlier clinical trial demonstrating the safety of an intra-vas deferens injection of a contraceptive drug named Risug, comprised of styrene maleic anhydride (SMA) in a solvent vehicle of dimethylsulphoxide (DMSO), a study to assess the contraceptive effectiveness of a specific do...

Full description

Saved in:

Bibliographic Details
Published in:	Contraception (Stoneham) 1997-10, Vol.56 (4), p.245-250
Main Authors:	Guha, Sujoy K., Singh, Gulshanjit, Ansari, Shirfuddin, Kumar, Sudheer, Srivastava, Anil, Koul, Veena, Das, H.C., Malhotra, R.L., Das, S.K.
Format:	Article
Language:	English
Subjects:	Adult Biological and medical sciences Birth control Contraceptive Agents, Male - administration & dosage Female Follow-Up Studies Gynecology. Andrology. Obstetrics Humans injectable male contraceptive Injections - methods Male Maleic Anhydrides - administration & dosage Medical sciences Oligospermia Other methods of contraception. Sterilization Polystyrenes - administration & dosage Population pregnancy protection Spermatozoa - drug effects styrene maleic anhydride Vas Deferens
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c389t-fed247706e6ecd4a8d18716946df504c283747c0a005d01b6f8d62198dccc2b83
cites	cdi_FETCH-LOGICAL-c389t-fed247706e6ecd4a8d18716946df504c283747c0a005d01b6f8d62198dccc2b83
container_end_page	250
container_issue	4
container_start_page	245
container_title	Contraception (Stoneham)
container_volume	56
creator	Guha, Sujoy K. Singh, Gulshanjit Ansari, Shirfuddin Kumar, Sudheer Srivastava, Anil Koul, Veena Das, H.C. Malhotra, R.L. Das, S.K.
description	Following up on an earlier clinical trial demonstrating the safety of an intra-vas deferens injection of a contraceptive drug named Risug, comprised of styrene maleic anhydride (SMA) in a solvent vehicle of dimethylsulphoxide (DMSO), a study to assess the contraceptive effectiveness of a specific dose (60 mg) of SMA bilaterally was planned and implemented. Male subjects and their wives with normal reproductive profiles were the volunteer subjects. The wives were not using any contraceptives. The results reconfirm the safety and show that for a period of at least 1 year, the treatment leads to azoospermia in the male and gives pregnancy protection.
doi_str_mv	10.1016/S0010-7824(97)00142-X
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79477913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S001078249700142X</els_id><sourcerecordid>79477913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-fed247706e6ecd4a8d18716946df504c283747c0a005d01b6f8d62198dccc2b83</originalsourceid><addsrcrecordid>eNqFkE1rGzEQhkVJcB2nPyGgQwnNYdvRfkk6hWD6YTC40AZ8E_JoRBTWu460NvTfR4mNr72MGOaZ0cvD2I2ArwJE--0PgIBCqrL-ouVdbuqyWH9gU6GkLqAR6oJNz8hHdpXSMwBI3cgJm-galIR2yla_n2wivlhw7EIf0HZ8jCHXwXPLDzZxR54i9YmH_plwtJuOOA79GC3SbgwH4n6IfHwivrUdXbNLb7tEn07vjD3--P53_qtYrn4u5g_LAiulx8KTK2uZE1BL6GqrXI4tWl23zjdQY6kqWUsEC9A4EJvWK9eWQiuHiOVGVTN2e7y7i8PLntJotiEhdZ3tadgnI3U-r0WVweYIYhxSiuTNLoatjf-MAPMm0ryLNG-WjJbmXaRZ572b0wf7zZbceetkLs8_n-Y2ZWs-2h5DOmMlyEoryNj9EaMs4xAomoSBeiQXYrZp3BD-E-QVKEyOoQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79477913</pqid></control><display><type>article</type><title>Phase II clinical trial of a vas deferens injectable contraceptive for the male</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Guha, Sujoy K. ; Singh, Gulshanjit ; Ansari, Shirfuddin ; Kumar, Sudheer ; Srivastava, Anil ; Koul, Veena ; Das, H.C. ; Malhotra, R.L. ; Das, S.K.</creator><creatorcontrib>Guha, Sujoy K. ; Singh, Gulshanjit ; Ansari, Shirfuddin ; Kumar, Sudheer ; Srivastava, Anil ; Koul, Veena ; Das, H.C. ; Malhotra, R.L. ; Das, S.K.</creatorcontrib><description>Following up on an earlier clinical trial demonstrating the safety of an intra-vas deferens injection of a contraceptive drug named Risug, comprised of styrene maleic anhydride (SMA) in a solvent vehicle of dimethylsulphoxide (DMSO), a study to assess the contraceptive effectiveness of a specific dose (60 mg) of SMA bilaterally was planned and implemented. Male subjects and their wives with normal reproductive profiles were the volunteer subjects. The wives were not using any contraceptives. The results reconfirm the safety and show that for a period of at least 1 year, the treatment leads to azoospermia in the male and gives pregnancy protection.</description><identifier>ISSN: 0010-7824</identifier><identifier>EISSN: 1879-0518</identifier><identifier>DOI: 10.1016/S0010-7824(97)00142-X</identifier><identifier>PMID: 9408706</identifier><identifier>CODEN: CCPTAY</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Biological and medical sciences ; Birth control ; Contraceptive Agents, Male - administration & dosage ; Female ; Follow-Up Studies ; Gynecology. Andrology. Obstetrics ; Humans ; injectable male contraceptive ; Injections - methods ; Male ; Maleic Anhydrides - administration & dosage ; Medical sciences ; Oligospermia ; Other methods of contraception. Sterilization ; Polystyrenes - administration & dosage ; Population ; pregnancy protection ; Spermatozoa - drug effects ; styrene maleic anhydride ; Vas Deferens</subject><ispartof>Contraception (Stoneham), 1997-10, Vol.56 (4), p.245-250</ispartof><rights>1997</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-fed247706e6ecd4a8d18716946df504c283747c0a005d01b6f8d62198dccc2b83</citedby><cites>FETCH-LOGICAL-c389t-fed247706e6ecd4a8d18716946df504c283747c0a005d01b6f8d62198dccc2b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2073980$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9408706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guha, Sujoy K.</creatorcontrib><creatorcontrib>Singh, Gulshanjit</creatorcontrib><creatorcontrib>Ansari, Shirfuddin</creatorcontrib><creatorcontrib>Kumar, Sudheer</creatorcontrib><creatorcontrib>Srivastava, Anil</creatorcontrib><creatorcontrib>Koul, Veena</creatorcontrib><creatorcontrib>Das, H.C.</creatorcontrib><creatorcontrib>Malhotra, R.L.</creatorcontrib><creatorcontrib>Das, S.K.</creatorcontrib><title>Phase II clinical trial of a vas deferens injectable contraceptive for the male</title><title>Contraception (Stoneham)</title><addtitle>Contraception</addtitle><description>Following up on an earlier clinical trial demonstrating the safety of an intra-vas deferens injection of a contraceptive drug named Risug, comprised of styrene maleic anhydride (SMA) in a solvent vehicle of dimethylsulphoxide (DMSO), a study to assess the contraceptive effectiveness of a specific dose (60 mg) of SMA bilaterally was planned and implemented. Male subjects and their wives with normal reproductive profiles were the volunteer subjects. The wives were not using any contraceptives. The results reconfirm the safety and show that for a period of at least 1 year, the treatment leads to azoospermia in the male and gives pregnancy protection.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Birth control</subject><subject>Contraceptive Agents, Male - administration & dosage</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>injectable male contraceptive</subject><subject>Injections - methods</subject><subject>Male</subject><subject>Maleic Anhydrides - administration & dosage</subject><subject>Medical sciences</subject><subject>Oligospermia</subject><subject>Other methods of contraception. Sterilization</subject><subject>Polystyrenes - administration & dosage</subject><subject>Population</subject><subject>pregnancy protection</subject><subject>Spermatozoa - drug effects</subject><subject>styrene maleic anhydride</subject><subject>Vas Deferens</subject><issn>0010-7824</issn><issn>1879-0518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNqFkE1rGzEQhkVJcB2nPyGgQwnNYdvRfkk6hWD6YTC40AZ8E_JoRBTWu460NvTfR4mNr72MGOaZ0cvD2I2ArwJE--0PgIBCqrL-ouVdbuqyWH9gU6GkLqAR6oJNz8hHdpXSMwBI3cgJm-galIR2yla_n2wivlhw7EIf0HZ8jCHXwXPLDzZxR54i9YmH_plwtJuOOA79GC3SbgwH4n6IfHwivrUdXbNLb7tEn07vjD3--P53_qtYrn4u5g_LAiulx8KTK2uZE1BL6GqrXI4tWl23zjdQY6kqWUsEC9A4EJvWK9eWQiuHiOVGVTN2e7y7i8PLntJotiEhdZ3tadgnI3U-r0WVweYIYhxSiuTNLoatjf-MAPMm0ryLNG-WjJbmXaRZ572b0wf7zZbceetkLs8_n-Y2ZWs-2h5DOmMlyEoryNj9EaMs4xAomoSBeiQXYrZp3BD-E-QVKEyOoQ</recordid><startdate>19971001</startdate><enddate>19971001</enddate><creator>Guha, Sujoy K.</creator><creator>Singh, Gulshanjit</creator><creator>Ansari, Shirfuddin</creator><creator>Kumar, Sudheer</creator><creator>Srivastava, Anil</creator><creator>Koul, Veena</creator><creator>Das, H.C.</creator><creator>Malhotra, R.L.</creator><creator>Das, S.K.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19971001</creationdate><title>Phase II clinical trial of a vas deferens injectable contraceptive for the male</title><author>Guha, Sujoy K. ; Singh, Gulshanjit ; Ansari, Shirfuddin ; Kumar, Sudheer ; Srivastava, Anil ; Koul, Veena ; Das, H.C. ; Malhotra, R.L. ; Das, S.K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-fed247706e6ecd4a8d18716946df504c283747c0a005d01b6f8d62198dccc2b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Birth control</topic><topic>Contraceptive Agents, Male - administration & dosage</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>injectable male contraceptive</topic><topic>Injections - methods</topic><topic>Male</topic><topic>Maleic Anhydrides - administration & dosage</topic><topic>Medical sciences</topic><topic>Oligospermia</topic><topic>Other methods of contraception. Sterilization</topic><topic>Polystyrenes - administration & dosage</topic><topic>Population</topic><topic>pregnancy protection</topic><topic>Spermatozoa - drug effects</topic><topic>styrene maleic anhydride</topic><topic>Vas Deferens</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guha, Sujoy K.</creatorcontrib><creatorcontrib>Singh, Gulshanjit</creatorcontrib><creatorcontrib>Ansari, Shirfuddin</creatorcontrib><creatorcontrib>Kumar, Sudheer</creatorcontrib><creatorcontrib>Srivastava, Anil</creatorcontrib><creatorcontrib>Koul, Veena</creatorcontrib><creatorcontrib>Das, H.C.</creatorcontrib><creatorcontrib>Malhotra, R.L.</creatorcontrib><creatorcontrib>Das, S.K.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Contraception (Stoneham)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guha, Sujoy K.</au><au>Singh, Gulshanjit</au><au>Ansari, Shirfuddin</au><au>Kumar, Sudheer</au><au>Srivastava, Anil</au><au>Koul, Veena</au><au>Das, H.C.</au><au>Malhotra, R.L.</au><au>Das, S.K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II clinical trial of a vas deferens injectable contraceptive for the male</atitle><jtitle>Contraception (Stoneham)</jtitle><addtitle>Contraception</addtitle><date>1997-10-01</date><risdate>1997</risdate><volume>56</volume><issue>4</issue><spage>245</spage><epage>250</epage><pages>245-250</pages><issn>0010-7824</issn><eissn>1879-0518</eissn><coden>CCPTAY</coden><abstract>Following up on an earlier clinical trial demonstrating the safety of an intra-vas deferens injection of a contraceptive drug named Risug, comprised of styrene maleic anhydride (SMA) in a solvent vehicle of dimethylsulphoxide (DMSO), a study to assess the contraceptive effectiveness of a specific dose (60 mg) of SMA bilaterally was planned and implemented. Male subjects and their wives with normal reproductive profiles were the volunteer subjects. The wives were not using any contraceptives. The results reconfirm the safety and show that for a period of at least 1 year, the treatment leads to azoospermia in the male and gives pregnancy protection.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9408706</pmid><doi>10.1016/S0010-7824(97)00142-X</doi><tpages>6</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0010-7824
ispartof	Contraception (Stoneham), 1997-10, Vol.56 (4), p.245-250
issn	0010-7824 1879-0518
language	eng
recordid	cdi_proquest_miscellaneous_79477913
source	Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
subjects	Adult Biological and medical sciences Birth control Contraceptive Agents, Male - administration & dosage Female Follow-Up Studies Gynecology. Andrology. Obstetrics Humans injectable male contraceptive Injections - methods Male Maleic Anhydrides - administration & dosage Medical sciences Oligospermia Other methods of contraception. Sterilization Polystyrenes - administration & dosage Population pregnancy protection Spermatozoa - drug effects styrene maleic anhydride Vas Deferens
title	Phase II clinical trial of a vas deferens injectable contraceptive for the male
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-31T23%3A42%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20clinical%20trial%20of%20a%20vas%20deferens%20injectable%20contraceptive%20for%20the%20male&rft.jtitle=Contraception%20(Stoneham)&rft.au=Guha,%20Sujoy%20K.&rft.date=1997-10-01&rft.volume=56&rft.issue=4&rft.spage=245&rft.epage=250&rft.pages=245-250&rft.issn=0010-7824&rft.eissn=1879-0518&rft.coden=CCPTAY&rft_id=info:doi/10.1016/S0010-7824(97)00142-X&rft_dat=%3Cproquest_cross%3E79477913%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c389t-fed247706e6ecd4a8d18716946df504c283747c0a005d01b6f8d62198dccc2b83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79477913&rft_id=info:pmid/9408706&rfr_iscdi=true